Monitor for HCR Molag's potential sale of up to 400,000 shares which could create downward pressure on stock price. The minimal proceeds to Atara ($40) suggest this is not a capital raise but rather facilitating an investor exit. Watch for warrant exercise which would provide nominal cash but increase share count.
Price Chart
Executive Summary
Atara Biotherapeutics has filed an S-3 shelf registration to register 400,000 shares of common stock for resale by HCR Molag Fund, L.P., a selling stockholder. These shares are issuable upon exercise of a warrant granted in connection with an amendment to a purchase agreement that extended the due date of a $9.0 million milestone payment from June 2026 to January 2028. Atara will not receive proceeds from the resale, but may receive $0.04 from the warrant exercise. The offering represents a 4.9% dilution based on current market cap.
Key Financial Metrics
Key Facts
- S-3 filing registers 400,000 shares for resale by HCR Molag Fund, L.P.
- Shares are issuable upon exercise of a warrant with $0.0001 exercise price.
- Warrant was issued in connection with extending a $9.0 million milestone payment due date from June 2026 to January 2028.
- Atara will not receive proceeds from the resale of shares by the selling stockholder.
- Atara may receive $40 from warrant exercise (400,000 shares × $0.0001).
- Offering represents 4.9% of current shares outstanding (8.178M).
- Current market cap is $42M with stock price at $6.50.
Financial Impact
Potential $40 in proceeds to Atara from warrant exercise; 4.9% potential dilution from resale
Risk Factors
- Potential stock price pressure from HCR Molag selling up to 400,000 shares
- Dilution of existing shareholders if warrant is exercised and shares are sold
- Market perception of insider selling despite being a contractual obligation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-110849 |
| Document: d100379dexfilingfees.htm | 0001193125-26-110849 |
| Document: d100379dex51.htm | 0001193125-26-110849 |
| Document: d100379dex231.htm | 0001193125-26-110849 |
| Document: 0001193125-26-110849-index-headers.html | 0001193125-26-110849 |
| Document: 0001193125-26-110849-index.html | 0001193125-26-110849 |
| Document: 0001193125-26-110849.txt | 0001193125-26-110849 |
| CONTEXT: 10-Q (2025-11-12) | 0001193125-25-276219 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 26, 2026 14w ago | 8-K | $11.17 $8.93 | ▼ −20.05% | ▼ −24.44% | $9.48 (−15.13%) |
Jun 15, 2026 15w ago | 3 | $9.62 $9.89 | ▲ +2.81% | ▲ +1.81% | $9.48 (−1.46%) |
May 7, 2026 21w ago | 8-K | $9.93 $8.55 | ▼ −13.90% | ▼ −17.73% | $9.48 (−4.53%) |
May 7, 2026 21w ago | Insider Cluster | $9.93 $8.55 | ▼ −13.90% | ▼ −17.73% | $9.48 (−4.53%) |
Apr 24, 2026 23w ago | DEFA14A | $4.99 $8.13 | ▲ +62.83% | ▲ +58.05% | $9.48 (+89.98%) |
Mar 17, 2026 28w ago | S-3 | $5.00 $10.46 | ▲ +109.20% | ▲ +97.67% | $9.48 (+89.60%) |
Mar 12, 2026 29w ago | 8-K | $6.90 $9.92 | ▲ +43.77% | ▲ +33.07% | $9.48 (+37.39%) |
Mar 3, 2026 30w ago | 8-K | $5.42 $10.54 | ▲ +94.46% | ▲ +84.15% | $9.48 (+74.91%) |
Mar 2, 2026 30w ago | Insider Cluster | $4.91 $9.61 | ▲ +95.72% | ▲ +86.40% | $9.48 (+93.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access